Traditional treatment methods and biological agents play an important role in the treatment of rheumatizing diseases, and patients and doctors need to combine multiple factors to make the right choices.
Traditional treatment methods include, inter alia, non-paralytic anti-inflammatory (NSAIDs), improved rheumatism (DMARDs) and sugary cortex hormones. Non-synthetic anti-inflammation drugs, such as aspirin, Broven and others, are the front-line drugs for the treatment of rheumatizing diseases. They are effective in reducing inflammation and pain and have a rapid and visible effect on the patient ‘ s symptoms of joint pain and muscle pain. However, NSAIDs cannot change the course of the disease and long-term or large-scale use may cause adverse gastrointestinal effects such as stomach ulcer, haemorrhage and damage to kidney function.
Improved rheumatism is the cornerstone of the treatment of rheumatizing diseases. Like ammonium butterflies and fluorine-based drugs, immune responses can be inhibited, thus slowing the progress of disease. These drugs usually require long-term use in order to achieve better results and may take weeks or even months to see significant results at an early stage of treatment. The adverse effects of DMARDs are also more evident, such as the potential for liver function damage, bone marrow inhibition, etc. However, they can effectively control the condition and reduce the occurrence of serious consequences, such as joint malformations, when the dose is reasonably monitored and adjusted.
Sugar cortex hormones are a double-edged sword that can rapidly reduce inflammation and the suffering of patients during the acute onset of rheumatizing immune diseases. For example, during the acute onset phase of diseases such as rheumatism, systemic erythroacne, sugary hormonals such as Ponesson can quickly control symptoms. However, the long-term use of sugar cortex hormones can lead to a series of serious complications, such as osteoporosis, cardiac obesity, high blood pressure, diabetes, etc., and can easily re-emerge if mistreated during reduction or withdrawal.
Biological agents represent a new breakthrough in recent years in the field of rheumatism immunization treatment. Biological agents are primarily targeted for specific cell factors or cell surface molecules involved in the immune response. In the case of tumour cause of death – α (TNF – α) constrictors, these biological agents are very effective for diseases such as rheumatism arthritis and high-line spina. They can specifically disrupt the activity of TNF-α, reduce the inflammation response, rapidly improve the symptoms and function of the patient ‘ s joints, and are more effective than traditional DMARDs in stopping joint damage.
The advantage of biological agents over traditional treatments is that they are more target-oriented and more accurately able to act on disease-related target points, so that they are more effective and more effective. Also, in the case of adverse reactions, biological agents do not cause adverse reactions to the whole-body multisystems like sugar cortex hormones, and gastrointestinal responses are relatively low. However, biological agents are not perfect. Its greatest disadvantage is its high cost, which makes it difficult for many patients to afford for the long term. In addition, biological agents may increase the risk of infection, such as tuberculosis, viral infections, etc., which require a full assessment of the patient prior to use, including infection screening.
In selecting traditional treatment or biological agents, the severity of the disease is the primary consideration. For patients with less serious conditions, such as early rheumatism, the symptoms of the joints are not severe, and traditional DMFAS treatments may be effective in controlling the condition. Biological agents may be a better option if the patient is seriously ill, if serious joint malformations or multiple systems are already present. Secondly, consideration should be given to the financial situation of the patient. Because of the high cost of biological agents, traditional treatment may be a more practical option if the patient has limited financial means, while improving efficacy and reducing adverse effects by optimizing treatment programmes. In addition, consideration should be given to the age of the patient, his/her gender, and whether he/she has complications. For example, for older patients, the risk of using sugar-coated hormones may be higher and needs to be carefully weighed; for women of reproductive age, some traditional medicines may have adverse effects on the foetus, and the safety of biological agents in this regard needs to be further assessed.
In general, the traditional treatment of rheumatism and biological agents have advantages and disadvantages, which require a combination of disease characteristics, the individual circumstances of the patient and economic factors in order to choose the most appropriate treatment for the patient.
